Patheon is awaiting finalization of a $7.2 billion deal that will make it a part of Thermo Fisher Scientific, but in the meantime the CDMO is moving forward with expansion plans at sites that stretch from the West Coast of
read moreFacing persistent manufacturing difficulties, New Jersey-based Pacira Pharmaceuticals will stop producing chemo drug DepoCyte, taking a $5 million charge and laying off some employees as it winds down those operations at a plant in California. More: Pacira halts production of
read moreHigh-profile investor Neil Woodford isn’t the only one worried about GlaxoSmithKline’s HIV prospects. Wednesday, the British drugmaker’s shares sank as Citigroup downgraded the stock from buy to neutral and cut Glaxo earnings forecasts by up to 9%, Reuters reports. And
read moreIn the wake of last week’s canceled buyout, Stada’s CEO and CFO have left the company, and new buyout talk has already sprung up. The company announced the resignations of CEO Matthias Wiedenfels and CFO Helmut Kraft after a board
read moreDespite some early predictions that transparency would change everything, drug and device makers’ payments to doctors have remained remarkably consistent since their 2014 debut. All told, 631,000 doctors collected $2.8 billion in general payments in 2016, roughly the same as
read moreA new method for extracting prostate biopsies has been awarded a £789,000 Invention for Innovation (i4i) Product Development Award by the National Institute for Health Research (NIHR). More: Pioneering prostate biopsy device wins NIHR award Source: News
read more© 1994 - 2026 B.M. Pharmaceuticals